A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Authors

Sven de Vos, University of California - Los Angeles
Andres Forero-Torres, University of Alabama - BirminghamFollow
Stephen M. Ansell, Mayo Clinic Rochester
Brad Kahl, University of Wisconsin - Madison
Bruce D. Cheson, Georgetown University
Nancy L. Bartlett, Washington University School of Medicine in St. Louis
Richard R. Furman, Cornell University
Jane N. Winter, Northwestern University
Henry Kaplan, Swedish Cancer Institute
John Timmerman, University of California - Los Angeles
Nancy C. Whiting, Seattle Genetics, Inc.
Jonathan G. Drachman, Seattle Genetics, Inc.
Ranjana Advani, Stanford University

Journal

Journal of Hematology & Oncology

Publication Date

2014

Volume

7

Inclusive Pages

44

Document Type

Open Access Publication

Rights and Permissions

de Vos et al. Journal of Hematology & Oncology 2014, 7:44 http://www.jhoonline.org/content/7/1/44

Recommended Citation

de Vos, Sven; Forero-Torres, Andres; Ansell, Stephen M.; Kahl, Brad; Cheson, Bruce D.; Bartlett, Nancy L.; Furman, Richard R.; Winter, Jane N.; Kaplan, Henry; Timmerman, John; Whiting, Nancy C.; Drachman, Jonathan G.; and Advani, Ranjana, "A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors." Journal of Hematology & Oncology. 7, 44. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2991